ArticleInternational journal of clinical and health psychology : IJCHP
Placebo mechanisms in aging: A randomized controlled trial comparing deceptive and open-label placebos on psychological, cognitive, and physical functioning in older adults.
Article in International journal of clinical and health psychology : IJCHP. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: No study has yet examined whether a placebo in its traditional meaning-an inert treatment presented as active-can influence functions that tend to naturally decline with age. We aimed to clarify whether a deceptive and open-label placebo procedure would affect psychological, cognitive, and physical functioning in community-dwelling older adults. Methods: Ninety healthy older adults were randomly assigned to one of three conditions: a control group receiving no intervention; a deceptive placebo group receiving placebo pills along with information that these contained active ingredients known to improve functioning and well-being; an open-label placebo group, explicitly informed that the pills were inert but capable of eliciting beneficial mind-body responses. Participants completed self-report measures (perceived stress, psychological well-being, sleepiness, fatigue, optimism, self-efficacy, aging stereotypes) and objective tests of short-term memory, selective attention, and physical performance before and after the 3-week intervention. Results: After 3 weeks, the open-label placebo group exhibited lower perceived stress compared with both the deceptive placebo and control groups. Short-term memory performance also significantly improved in the open-label placebo group relative to controls. Within-group analyses revealed consistent cognitive and physical improvements in both placebo groups, with particularly pronounced effects in the open-label placebo group. Conclusions: Placebo interventions enhanced multiple domains of functioning in older adults, with open-label placebos producing benefits comparable to or greater than deceptive placebos. These findings suggest the potential of open-label placebos as a promising, ethically acceptable approach for supporting healthy aging.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.